SCHEMBL25259131

SCHEMBL25259131

c1ccc(-c2[nH]cnc2-c2ccc3c(c2)COC3)nc1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.44
IDO1 P14902 5/20 0.40
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
TGFBR1 P36897 7/20 0.38
MAPK14 Q16539 4/20 0.36
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
NPY5R Q15761 2/20 0.35
ACVR1B P36896 1/20 0.35
PDK2 Q15119 1/20 0.34
BRAF P15056 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25842016 0.81 TGFBR1 (0.40) IDO1TGFBR1MAPK14ACVR1B
SCHEMBL25842013 0.80 MAPK14 (0.40) IDO1CYP3A4TGFBR1MAPK14MAPK13
SCHEMBL25302190 0.79 SYK (0.44) SYKKDM4ECYP3A4MAPTTGFBR1
SCHEMBL30387353 0.77 BRAF (0.42) SYKKDM4ECYP3A4MAPTTGFBR1
SCHEMBL25302657 0.77 BRAF (0.42) SYKKDM4ECYP3A4MAPTTGFBR1
SCHEMBL30139830 0.77 TGFBR1 (0.55) IDO1KDM4ECYP3A4MAPTTGFBR1
SCHEMBL15188295 0.77 TGFBR1 (0.57) KDM4ECYP3A4MAPTTGFBR1MAPK14
SCHEMBL30635236 0.74 KDM4E (0.50) KDM4ECYP3A4MAPTTGFBR1NPY5R
SCHEMBL23418795 0.70 TNIK (0.41) IDO1KDM4ECYP3A4MAPTTGFBR1
SCHEMBL25822608 0.70 IDO1 (0.45) IDO1KDM4ECYP3A4MAPTTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473274-B2 Heterocyclic compound as inhibitor of casein kinase 1-δ and/or activin receptor-like kinase 5 ALCHEMEDICINE, INC. (JP) 2025-11-18 US disclosed
US-20230183220-A1 HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1-DELTA AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 ALCHEMEDICINE, INC. (JP) 2023-06-15 US disclosed
US-20230183220-A1 HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1-DELTA AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 ALCHEMEDICINE, INC. (JP) 2023-06-15 US disclosed
US-20230183220-A1 HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1-DELTA AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 ALCHEMEDICINE, INC. (JP) 2023-06-15 US disclosed
EP-4174061-A1 HETEROCYCLIC COMPOUND AS INHIBITOR FOR CASEIN KINASE 1d AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 Alchemedicine, Inc. (JP) 2023-05-03 EP disclosed
EP-4174061-A1 HETEROCYCLIC COMPOUND AS INHIBITOR FOR CASEIN KINASE 1d AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 Alchemedicine, Inc. (JP) 2023-05-03 EP disclosed
CN-116034105-A Heterocyclic compounds as inhibitors of casein kinase 1 delta and/or activin receptor-like kinase 5 亚克医药株式会社 2023-04-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183220-A1 HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1-DELTA AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 CSNK1A1, CSNK1G1, CSNK1D SYK 1739/4885IDO1 633/4885KDM4E 1022/4885
US-12473274-B2 Heterocyclic compound as inhibitor of casein kinase 1-δ and/or activin receptor-like kinase 5 CSNK1A1, CSNK1G1, CKS1B SYK 1743/4885IDO1 578/4885KDM4E 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.